Overview

OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal Women

Status:
Completed

Trial end date:
2007-03-01

Target enrollment:

Participant gender:

Summary

To determine how prior therapy with alendronate or risedronate in postmenopausal women with osteoporosis influences the clinical effectiveness of teriparatide; The primary objective of the study is to compare the teriparatide (human, recombinant PTH[1-34])-associated change from baseline in a marker of bone formation, N-terminal propeptide of type I collagen (P1NP), between subjects previously treated with risedronate and those previously treated with alendronate.

Phase:

Phase 4

Details

Lead Sponsor:

Sanofi

Collaborator:

Procter and Gamble

Treatments:

Alendronate
Etidronic Acid
Risedronate Sodium
Risedronic Acid
Teriparatide